Abstract
The Badimon perfusion chamber is an ex vivo model of thrombosis that assesses the thrombogenicity of blood in humans and large animals. It works with native blood thereby excluding any interfering effects of anticoagulants unavoidable with the majority of platelet function testing methodologies. Each variable of the Virchow’s triad (blood, blood flow, and endothelial wall) that modulates blood–vessel wall interaction and thrombus formation is incorporated in this perfusion model. These features make this device a valuable tool for the assessment of thrombogenic potential of various diseases and also gauging the efficacy of antithrombotic (anticoagulant and antiplatelet) treatments.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Santos-Gallego CG, Picatoste B, Badimon JJ (2014) Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep 16(4):401. https://doi.org/10.1007/s11883-014-0401-9
Santos-Gallego CG, Bayon J, Badimon JJ (2010) Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med 12(3):274–291. https://doi.org/10.1007/s11936-010-0075-8
Osende JI, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Heflt G, Fallon JT, Crandall JP (2001) Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 38(5):1307–1312
Badimon L, Badimon JJ, Galvez A, Turitto V, Fuster V (1989) Platelet interaction with vessel wall and collagen in pigs with homozygous von Willebrand’s disease associated with abnormal collagen aggregation. Thromb Haemost 61(1):57–64
Glassberg J, Rahman AH, Zafar MU, Cromwell C, Punzalan A, Badimon JJ, Aledort L (2018) Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis. J Immunol Methods 453:11–19. https://doi.org/10.1016/j.jim.2017.07.014
Badimon JJ, Badimon L, Turitto VT, Fuster V (1991) Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb 11(2):395–402
Shechter M, Merz CN, Paul-Labrador MJ, Kaul S (2000) Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J Am Coll Cardiol 35(2):300–307
Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V (1986) Influence of arterial damage and wall shear rate on platelet deposition. Ex vivo study in a swine model. Arteriosclerosis 6(3):312–320
Badimon L, Chesebro JH, Badimon JJ (1992) Thrombus formation on ruptured atherosclerotic plaques and rethrombosis on evolving thrombi. Circulation 86(6 Suppl):III74–III85
Lucking AJ, Lundback M, Mills NL, Faratian D, Barath SL, Pourazar J, Cassee FR, Donaldson K, Boon NA, Badimon JJ, Sandstrom T, Blomberg A, Newby DE (2008) Diesel exhaust inhalation increases thrombus formation in man. Eur Heart J 29(24):3043–3051. https://doi.org/10.1093/eurheartj/ehn464
Lucking AJ, Lundback M, Barath SL, Mills NL, Sidhu MK, Langrish JP, Boon NA, Pourazar J, Badimon JJ, Gerlofs-Nijland ME, Cassee FR, Boman C, Donaldson K, Sandstrom T, Newby DE, Blomberg A (2011) Particle traps prevent adverse vascular and prothrombotic effects of diesel engine exhaust inhalation in men. Circulation 123(16):1721–1728. CIRCULATIONAHA.110.987263 [pii]. https://doi.org/10.1161/CIRCULATIONAHA.110.987263
Mailhac A, Badimon JJ, Fallon JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L (1994) Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelets. Circulation 90(2):988–996
Badimon L, Badimon JJ (1989) Mechanisms of arterial thrombosis in nonparallel streamlines: platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 84(4):1134–1144. https://doi.org/10.1172/JCI114277
Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L (1994) Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23(7):1562–1569. 0735-1097(94)90657-2 [pii]
Badimon L, Badimon JJ, Turitto VT, Fuster V (1989) Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate; the importance of perfusion conditions. Blood 73(4):961–967
Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH (2007) Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost 97(3):487–492
Zafar MU, Ibanez B, Choi BG, Vorchheimer DA, Pinero A, Jin X, Sharma RK, Badimon JJ (2010) A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost 103(1):205–212. https://doi.org/10.1160/TH09-06-0378
Zafar MU, Vilahur G, Choi BG, Ibanez B, Viles-Gonzalez JF, Salas E, Badimon JJ (2007) A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost 5(6):1195–1200. https://doi.org/10.1111/j.1538-7836.2007.02543.x
Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ (2007) Antithrombotic effects of factor Xa inhibition with DU-176b: phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost 98(4):883–888
Zafar MU, Zafar M, Baber U, Smith DA, Sartori S, Contreras J, Rey-Mendoza J, Linares-Koloffon CA, Escolar G, Mehran R, Fuster V, Badimon JJ (2017) Antithrombotic potency of ticagrelor versus clopidogrel in type-2 diabetic patients with cardiovascular disease. Thromb Haemost 117(10):1981–1988. https://doi.org/10.1160/TH17-04-0277
Dangas G, Badimon JJ, Smith DA, Unger AH, Levine D, Shao JH, Meraj P, Fier C, Fallon JT, Ambrose JA (1999) Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 33(5):1294–1304
Hayes R, Chesebro JH, Fuster V, Dangas G, Fallon JT, Sharma SK, Coller BS, Badimon L, Marmur JD, Badimon JJ (2000) Antithrombotic effects of abciximab. Am J Cardiol 85(10):1167–1172
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Zafar, M.U., Santos-Gallego, C.G., Badimon, L., Badimon, J.J. (2018). Badimon Perfusion Chamber: An Ex Vivo Model of Thrombosis. In: Ishikawa, K. (eds) Experimental Models of Cardiovascular Diseases. Methods in Molecular Biology, vol 1816. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-8597-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-8597-5_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-8596-8
Online ISBN: 978-1-4939-8597-5
eBook Packages: Springer Protocols